Publications
Detailed Information
Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Juyoun | - |
dc.contributor.author | Joo, Kyeung Min | - |
dc.contributor.author | Nam, Yoonhee | - |
dc.contributor.author | Kim, Dae Hyun | - |
dc.contributor.author | Jo, Mi-Young | - |
dc.contributor.author | Kim, Hyeong-Seok | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Nam, Do-Hyun | - |
dc.contributor.author | Seo, Soo Won | - |
dc.contributor.author | Jin, Younggeon | - |
dc.contributor.author | Lee, Se Jeong | - |
dc.date.accessioned | 2012-07-09T08:09:12Z | - |
dc.date.available | 2012-07-09T08:09:12Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | EXPERIMENTAL AND THERAPEUTIC MEDICINE; Vol.1, No.6; 943-946 | ko_KR |
dc.identifier.issn | 1792-0981 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78664 | - |
dc.description.abstract | We hypothesized that methotrexate (MTX) normalizes the increased permeability of the blood-tumor barrier and thus reduces the accessibility of rituximab (RTX) to central nervous system (CNS) lymphoma. Here, we evaluated the combinational treatment capability of RTX and MTX using an alternative treatment schedule against CNS lymphoma. We developed a CNS lymphoma animal model that closely mimics the morphological and molecular characteristics of human CNS lymphoma by injecting Raji human Burkitt lymphoma cells into the brains of immune-compromised mice and tested a novel combinational treatment schedule by which penetration of RTX was not influenced by MTX administration. RTX was conjugated with Alexa Fluor 680, and its distribution in the brain was analyzed by in vivo imaging. When MTX treatment was followed by a 3-day post RTX administration, RTX was scarcely distributed in the brain, and there were only modest statistically insignificant therapeutic effects compared with the control mice which received sham injections. In contrast, RTX administration followed by a 3-day post MTX treatment showed significantly increased distribution of RTX and significantly reduced tumor volume in the brain. Collectively, our data demonstrate that RTX can be successfully combined with MTX using an alternative treatment schedule that allows increased distribution of RTX in CNS lymphoma. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPANDIDOS PUBL LTD | ko_KR |
dc.subject | central nervous system lymphoma | ko_KR |
dc.subject | rituximab | ko_KR |
dc.subject | methotrexate | ko_KR |
dc.subject | combination therapy | ko_KR |
dc.subject | mouse model | ko_KR |
dc.title | Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 진주연 | - |
dc.contributor.AlternativeAuthor | 주경민 | - |
dc.contributor.AlternativeAuthor | 남윤희 | - |
dc.contributor.AlternativeAuthor | 김대현 | - |
dc.contributor.AlternativeAuthor | 이세정 | - |
dc.contributor.AlternativeAuthor | 조미영 | - |
dc.contributor.AlternativeAuthor | 진영건 | - |
dc.contributor.AlternativeAuthor | 김형석 | - |
dc.contributor.AlternativeAuthor | 서수원 | - |
dc.contributor.AlternativeAuthor | 김석진 | - |
dc.contributor.AlternativeAuthor | 남도현 | - |
dc.contributor.AlternativeAuthor | 김원석 | - |
dc.identifier.doi | 10.3892/etm.2010.143 | - |
dc.citation.journaltitle | EXPERIMENTAL AND THERAPEUTIC MEDICINE | - |
dc.description.citedreference | Jahnke K, 2009, NEURO-ONCOLOGY, V11, P503, DOI 10.1215/15228517-2008-119 | - |
dc.description.citedreference | WANG W, 2006, NEUROSURG FOCUS, V21, pE14 | - |
dc.description.citedreference | Herrlinger U, 2005, ANN NEUROL, V57, P843 | - |
dc.description.citedreference | Enting RH, 2004, NEUROLOGY, V63, P901 | - |
dc.description.citedreference | Wong ET, 2004, CANCER, V101, P139, DOI 10.1002/cncr.20339 | - |
dc.description.citedreference | Neuwelt EA, 2004, NEUROSURGERY, V54, P131, DOI 10.1227/01.NEU.0000097715.11966.8E | - |
dc.description.citedreference | DeAngelis LM, 2002, J CLIN ONCOL, V20, P4643, DOI 10.1200/JCO.2002.11.013 | - |
dc.description.citedreference | Abrey LE, 2000, J CLIN ONCOL, V18, P3144 | - |
dc.description.citedreference | McLaughlin P, 1998, J CLIN ONCOL, V16, P2825 | - |
dc.description.citedreference | Neuwelt EA, 1998, CLIN CANCER RES, V4, P1549 | - |
dc.description.citedreference | Maloney DG, 1997, J CLIN ONCOL, V15, P3266 | - |
dc.description.citedreference | BARNETT PA, 1995, AM J PATHOL, V146, P436 | - |
dc.description.citedreference | NEUWELT EA, 1994, J NUCL MED, V35, P1831 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.